A Study in Myeloproliferative Disorders

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01134120
First received: May 27, 2010
Last updated: September 26, 2014
Last verified: September 2014

May 27, 2010
September 26, 2014
April 2010
April 2014   (final data collection date for primary outcome measure)
  • Determination of a recommended Phase 2 dosing regimen [ Time Frame: Time of first dose until last dose ] [ Designated as safety issue: Yes ]
  • Number of participants with clinical significant effects [ Time Frame: Time of first dose until last dose ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01134120 on ClinicalTrials.gov Archive Site
  • Preliminary pharmacokinetics of LY2784544 (Cmax) [ Time Frame: Part A1: Day 1,2,15, and 29; Part A2: Day 7, 14, 21, 28, 29, 56, and 57; Part B: Day 1, 29, 57, and 113 ] [ Designated as safety issue: No ]
  • Preliminary pharmacokinetics of LY2784544 (AUC) [ Time Frame: Part A1: Day 1,2,15, and 29; Part A2: Day 7, 14, 21, 28, 29, 56, and 57; Part B: Day 1, 29, 57, and 113 ] [ Designated as safety issue: No ]
  • Malignant clone burden [ Time Frame: Part A1: Baseline (2 times), Weeks 13, 21 and every 6 months while patient is on study; Parts A2 and B: Baseline (2 times), Weeks 5, 8, 17, 25 and every 6 months while patient is on study ] [ Designated as safety issue: No ]
  • Preliminary pharmacokinetics of LY2784544 (Cmax) [ Time Frame: Part A: Day 1,2,15, and 29; Part B: Day 1, 29, and 113 ] [ Designated as safety issue: No ]
  • Preliminary pharmacokinetics of LY2784544 (AUC) [ Time Frame: Part A: Day 1,2,15, and 29; Part B: Day 1, 29, and 113 ] [ Designated as safety issue: No ]
  • Malignant clone burden [ Time Frame: Baseline, Week 17, 25 and every 6 months while patient is on study ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Study in Myeloproliferative Disorders
A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders

The purpose of this study is to find out the safe dose range of the study drug in patients with myeloproliferative disorders.

The purpose of the study is to learn:

  1. How much and how often LY2784544 should be given to patients
  2. What is the safety profile of LY2784544 and any side effects that might be associated with it
  3. How LY2784544 is taken up, distributed, broken down, and passed out of your body
  4. Whether LY2784544 can help patients with myeloproliferative disorders
  5. If any markers in the blood (biomarkers) can identify patients who will respond better to the study drug.

The planned duration of the study is not fixed. The length of time patients participate in the study will be determined by the investigator/study doctor.

Part A of the study is to determine the dose of the study drug. Part A is divided into two sections, A1 and A2. In Part A1, patients will be given study drug without a lead-in period. In Parts A2 and B, patients will have a lead-in period of 2 or 4 weeks with a low dose of LY2784544 prior to taking a higher dose of LY2784544. Part B of the study is to confirm the safety of the dose and schedule.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Myeloproliferative Disorders
  • Thrombocythemia, Essential
  • Polycythemia Vera
  • Primary Myelofibrosis
Drug: LY2784544
LY2784544 will be supplied as a capsule. The study drug will be taken by mouth daily while the patient is on study. In this study, different patients will be treated at different doses of LY2784544 until reaching the highest dose that patients can tolerate.
Experimental: LY2784544
Intervention: Drug: LY2784544
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
80
February 2015
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have a diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) as defined by the World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms and meet the following additional sub-type specific criteria:

A. PV: has failed or is intolerant of standard therapies or refuses to take standard medications

B. ET: has failed or is intolerant of standard therapies or refuses to take standard medications

C. MF (patients with MF must meet at least one of the following):

i. has intermediate or high-risk MF according to the Lille scoring system; or

ii. has symptomatic MF with spleen greater than 10 cm below left costal margin; or

iii. has post-polycythemic MF; or

iv. has post-ET MF

  • Have a quantifiable JAK2 V617F mutation
  • Have discontinued all previous approved therapies for myeloproliferative disorders, including any chemotherapy, immunomodulating therapy (for example, thalidomide, interferon-alpha), immunosuppressive therapy (for example, corticosteroids greater than 10 mg/day prednisone or equivalent), radiotherapy, and erythropoietin, thrombopoietin, or granulocyte colony stimulating factor for at least 14 days and recovered from the acute effects of therapy. Hydroxyurea used to control blood cell counts is permitted at study entry if the subject has been maintained on a stable dose for at least 4 weeks. Low-dose acetylsalicylic acid (aspirin) is permitted as well

Exclusion Criteria:

  • Have received treatment within 14 days of the initial dose of study drug with an experimental agent that has not received regulatory approval for any indication
  • Are currently being treated with agents that are metabolized by CYP3A4 with a narrow therapeutic margin (for example, alfentanil, cyclosporine, diergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus) or CYP2B6 (for example, cyclophosphamide, ifosfamide, tamoxifen, efavirenz, propofol, methadone, and bupropion)
  • Are currently being treated with warfarin or one of its derivatives which is known to alter levels of protein C or protein S. An exception to this criterion will be allowed for patients with a prior history of Budd-Chiari Syndrome who are being treated with warfarin or one of its derivatives
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01134120
13201, I3X-MC-JHTA
No
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP